This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2024 Feb 9;5(2):169-171.

doi: 10.1016/j.medj.2024.01.013.

Olgotrelvir, a dual inhibitor of SARS-CoV-2 M^pro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19

PMID: 38340710
DOI: 10.1016/j.medj.2024.01.013

Free article

Published Erratum

Olgotrelvir, a dual inhibitor of SARS-CoV-2 M^pro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19

Long Mao et al. Med. 2024.

Free article

. 2024 Feb 9;5(2):169-171.

doi: 10.1016/j.medj.2024.01.013.

PMID: 38340710
DOI: 10.1016/j.medj.2024.01.013

No abstract available

PubMed Disclaimer

Erratum for

Olgotrelvir, a dual inhibitor of SARS-CoV-2 M^pro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Med. 2024 Jan 12;5(1):42-61.e23. doi: 10.1016/j.medj.2023.12.004. Epub 2024 Jan 4. Med. 2024. PMID: 38181791

Similar articles

Olgotrelvir, a dual inhibitor of SARS-CoV-2 M^pro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, Kushnareva Y, Powers C, Stegman K, Liu J, Xie H, Xu C, Bao Y, Xu L, Zhang Y, Yang H, Qian S, Hu Y, Shao J, Zhang C, Li T, Li Y, Liu N, Lin Z, Wang S, Wang C, Shen W, Lin Y, Shu D, Zhu Z, Kotoi O, Kerwin L, Han Q, Chumakova L, Teijaro J, Royal M, Brunswick M, Allen R, Ji H, Lu H, Xu X. Mao L, et al. Med. 2024 Jan 12;5(1):42-61.e23. doi: 10.1016/j.medj.2023.12.004. Epub 2024 Jan 4. Med. 2024. PMID: 38181791
SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
Tan B, Joyce R, Tan H, Hu Y, Wang J. Tan B, et al. Acc Chem Res. 2023 Jan 17;56(2):157-168. doi: 10.1021/acs.accounts.2c00735. Epub 2022 Dec 29. Acc Chem Res. 2023. PMID: 36580641 Free PMC article.
Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.
Ciaglia T, Vestuto V, Di Sarno V, Musella S, Smaldone G, Di Matteo F, Napolitano V, Miranda MR, Pepe G, Basilicata MG, Novi S, Capolupo I, Bifulco G, Campiglia P, Gomez-Monterrey I, Snoeck R, Andrei G, Manfra M, Ostacolo C, Lauro G, Bertamino A. Ciaglia T, et al. Eur J Med Chem. 2024 Feb 15;266:116128. doi: 10.1016/j.ejmech.2024.116128. Epub 2024 Jan 9. Eur J Med Chem. 2024. PMID: 38232463
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Pang X, Xu W, Liu Y, Li H, Chen L. Pang X, et al. Eur J Med Chem. 2023 Sep 5;257:115491. doi: 10.1016/j.ejmech.2023.115491. Epub 2023 May 22. Eur J Med Chem. 2023. PMID: 37244162 Free PMC article. Review.
Cathepsin L, transmembrane peptidase/serine subfamily member 2/4, and other host proteases in COVID-19 pathogenesis - with impact on gastrointestinal tract.
Berdowska I, Matusiewicz M. Berdowska I, et al. World J Gastroenterol. 2021 Oct 21;27(39):6590-6600. doi: 10.3748/wjg.v27.i39.6590. World J Gastroenterol. 2021. PMID: 34754154 Free PMC article. Review.

See all similar articles

Cited by

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo.
Chu H, Shuai H, Qiao J, Yoon C, Zhang G, Hou Y, Xia X, Wang L, Deng X, Wang Y, Li Q, Du L, Liu Y, Zhou M, Wong HT, Liu H, Hu B, Chen Y, Fang Z, Xia Z, Chai Y, Shi J, Wang Y, Zhu T, Zhang H, Yuan S, Zhou J, Chan J, Yuen KY, Xu C, Lei J, Yang S. Chu H, et al. Res Sq [Preprint]. 2024 Nov 21:rs.3.rs-5454588. doi: 10.21203/rs.3.rs-5454588/v1. Res Sq. 2024. Update in: Nat Commun. 2025 Jul 16;16(1):6541. doi: 10.1038/s41467-025-60832-z. PMID: 39606435 Free PMC article. Updated. Preprint.
Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.
Amblard F, LeCher JC, De R, Zhou S, Liu P, Goh SL, Tao S, Patel D, Downs-Bowen J, Zandi K, Zhang H, Chaudhry G, McBrayer T, Muczynski M, Al-Homoudi A, Engel J, Lan S, Sarafianos SG, Kovari LC, Schinazi RF. Amblard F, et al. Eur J Med Chem. 2024 Mar 15;268:116263. doi: 10.1016/j.ejmech.2024.116263. Epub 2024 Feb 24. Eur J Med Chem. 2024. PMID: 38432056 Free PMC article.
Identification of novel SARS-CoV-2 3CLpro inhibitors by molecular docking, in vitro assays, molecular dynamics simulations and DFT analyses.
Zong K, Wei C, Li W, Ruan J, Zhang S, Li J, Liu X, Zhao X, Cao R, Yan H, Li X. Zong K, et al. Front Pharmacol. 2024 Oct 30;15:1494953. doi: 10.3389/fphar.2024.1494953. eCollection 2024. Front Pharmacol. 2024. PMID: 39539614 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal